Randomized, Multicenter, Phase III Trial of Heptaplatin 1-hour Infusion and 5-Fluorouracil Combination Chemotherapy Comparing with Cisplatin and 5-Fluorouracil Combination Chemotherapy in Patients with Advanced Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose ; Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer. Materials and Methods ; One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1∼5 every 4 weeks. Results ; At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3∼4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatmentrelated deaths. Conclusion ; Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.
Abstract
Purpose ; Heptaplatin (Sunpla) is a cisplatin derivative. A phase IIb trial using heptaplatin resulted in a 34% response rate with mild nephrotoxicity. We conducted a randomized phase III trial of heptaplatin plus 5-FU compared with cisplatin plus 5-FU in patients with advanced gastric cancer. Materials and Methods ; One hundred seventy-four patients (heptaplatin, n=88; cisplatin, n=86) from 13 centers were enrolled. The eligibility criteria were as follows: patients with pathologically-proven adenocarcinoma, chemonaive patients, or patients who had received only single adjuvant chemotherapy, and who had a measurable or evaluable lesion. On day 1, heptaplatin (400mg/m2) or cisplatin (60 mg/m2) was given over 1 hour with 5-FU (1 gm/m2) on days 1∼5 every 4 weeks. Results ; At the time of survival analysis, the median overall survival was 7.3 months in the 5-FU + heptaplatin (FH) arm and 7.9 months in the 5-FU + cisplatin (FP) arm (p=0.24). Of the FH patients, 34.2% (complete response [CR], 1.3%; partial response [PR], 32.9%) experienced a confirmed objective response compared with 35.9% (CR 0%, PR 35.9%) of FP patients (p=0.78). The median-time-to-progression was 2.5 months in the FH arm and 2.3 months in the FP arm. The incidence of neutropenia was higher with FP (28%) than with FH (16%; p=0.06); grade 3∼4 nausea and vomiting were more frequent in the FP than in the FH arm (p=0.01 and p=0.05, respectively). The incidence of increased proteinuria and creatininemia was higher with FH than with FP; however, there was no statistical difference. There were no treatmentrelated deaths. Conclusion ; Heptaplatin showed similar effects to cisplatin when combined with 5-FU in advanced gastric cancer patients with tolerable toxicities.
참고문헌 (25)
- Jemal A, "Cancer statistics 2002", CA Cancer J Clin, 52, pp.23~47 (2002)
- Greenlee RT, "Cancer statistics 2001", CA Cancer J Clin, 51, pp.15~36 (2001)
- Kim NK, "A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer", Cancer, 71, pp.3813~3818 (1993)
- Ohtsu A, "Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)", J Clin Oncol, 21, pp.54~59 (2003)
- Fram RJ, "Cisplatin and platinum analogues: recent advances", Curr Opin Oncol, :, pp.1073~1079 (1992)
- Reed E, "Platinum analogues, in Cancer chemotherapy and biotherapy: principles and practice. 2nd.", pp.357~378 (1996), Lippincott-Raven
- Harrap KR, "Preclinical studies identifying carboplatin as a visible cisplatin alternative", Cancer Treat Rev, 12, pp.21~33 (1985)
- McKeage MJ, "Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium", Br J Cancer, 64, pp.788~792 (1991)
- Rose WC, "Preclinical antitumor and toxicologic profile of carboplatin", Cancer Treat Rev, 12, pp.1~19
- Gore ME, "Cisplatin", carboplatin cross-resistance in ovarian cancer, 1989, pp.60, 767~769
- platinum(II) complexes, "J Med Chem", 1994, 1471~1485
- platinum(II), a new platinum analogue, as an anticancer agent, "Cancer Chemother Pharmacol", 1995, 441~445
- platinum(II), "Cancer Chemother Pharmacol", 1998, 109~116
- Kim NK, "Phase II clinical trial of SKI-2053R, a new platinum analog, in the treatment of patients with advanced gastric adenocarcinoma", Cancer, 86, pp.1109~1115 (1999)
- Min Young Joo, "Combination Chemotherapy with 5-Fluorouracil and Heptaplatin as First-line Treatment in Patients with Advanced Gastric Cancer", Journal of Korean Medical Science, 19(3), pp.369~373 (2004), 대한의학회
- Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
- Hong WS, "In vitro antitumor activity of a new platinum complex, cis-malonato (4R,5R)-4,5-bis(aminomethyl)-1,3-dioxolane-platinum(II) (SKI 2053R), against human lung and stomach cancer cell lines", Anticancer Res, 15, pp.51~54 (1995)
- Loehrer PJ, "Drugs five years later. Cisplatin. Ann Intern Med", 100, pp.704~713 (1984)
- Madias NE, "Platinum nephrotoxicity", Am J Med, 65, pp.307~314 (1987)
- Moertel CG, "A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas", J Clin Oncol, 4, pp.1053~1057 (1986)
- Yeul Hong Kim, "Chemotherapy for Advanced Gastric Cancer: Slow but Further Progress", Cancer Research and Treatment, 37(2), pp.79~86 (2005), 대한암학회
- Ohtsu A, "Phase II study of protracted infusional 5-flurouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncoloty Group (JCOG)", Eur J Cancer, 30A, pp.2091~2093 (1994)
- Gormley PE, "Kinetics of cis-dichlorodiammineplatinum", Clin Pharmacol Ther, 25, pp.351~357 (1979)
- platinum(II) as determined by ex vivo pharmacodynamics, "Cancer Chemother pharmacol", 1995, 1~6
- Ahn JH, "Nephrotoxicity of heptaplatin: a randomized comparion with cisplatin in advanced gastric cancer", Cancer Chemother Pharmacol, 50, pp.104~110 (2002)